Rubella Vaccines
Standalone live-attenuated rubella vaccines (now administered as part of MMR)
This page catalogs 6 standalone rubella vaccine products spanning the US-licensed RA 27/3 strain and discontinued European formulations. Stanley Plotkin's RA 27/3 strain, developed using human diploid cells, became the global standard and remains the rubella component in all current MMR vaccines. Standalone rubella vaccination has been replaced entirely by combination products such as M-M-R II and Priorix.
Last updated: April 2026.
Rubella Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Meruvax II | Rubella virus vaccine, live (RA 27/3) | Merck | Live-attenuated viral | FDA Licensed; Discontinued | Standalone rubella; replaced by MMR |
| Cendevax | Rubella vaccine (Cendehill strain) | SKF/GSK | Live-attenuated viral | Licensed (UK); Discontinued | UK rubella vaccine |
| Almevax | Rubella vaccine (RA 27/3) | Wellcome | Live-attenuated viral | Licensed (UK); Discontinued | UK rubella product |
| Ervevax | Rubella vaccine (RA 27/3) | SKB/GSK | Live-attenuated viral | Licensed (EU); Discontinued | European rubella vaccine |
| Rubeovax | Rubella vaccine | Various | Live-attenuated viral | Discontinued | Historical rubella product |
| Rucelvax | Rubella vaccine | Various | Live-attenuated viral | Discontinued | Historical rubella product |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026). Historical context informed by Khan, Shaz, The Ultimate Vaccine Timeline.